Published In
European Journal of Rheumatology
Volume 9 · Issue 3
Pages: 176-179
History
Published Online: January 21, 2022
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © 2022 European Journal of Rheumatology
Cemal Bes
Department of Internal Medicine and
Rheumatology, University of Health
Sciences, Basaksehir C am and Sakura City
Hospital, _
Istanbul, Turkey
Gizem Köybaşı
Department of Chest Disease, Yedikule
Chest Diseases and Chest Surgery
Training and Research Hospital,
Istanbul, Turkey
Ozan Cemal İçaçan
Department of Rheumatology, University
of Health Sciences, Bakırko¨ y Dr. Sadi
Konuk, Training and Research Hospital,
Istanbul, Turkey
Melek Yalçın Mutlu
Department of Internal Medicine and
Rheumatology, University of Health
Sciences, Basaksehir C am and Sakura City
Hospital, _
Istanbul, Turkey
Fatih Yıldırım
Department of Internal Medicine and
Rheumatology, University of Health
Sciences, Basaksehir C am and Sakura City
Hospital, _
Istanbul, Turkey
Bes, C., Köybaşı, G., İçaçan, O. C., Mutlu, M. Y., & Yıldırım, F. (2022). Antifibrotic therapies in rheumatoid arthritis associated interstitial lung disease. European Journal of Rheumatology, 9(3), 176–179. https://doi.org/10.5152/eurjrheum.2021.21102
Full Text
Full Text PDF
Full Text PDF
Abstract
bstract Interstitial lung disease (ILD) is one of the common extra-articular manifestations of rheumatoid arthritis (RA) and it is associated with high mortality rate. The usual interstitial pneumonia (UIP) pattern of RA associated ILD (RA-ILD) shows some similarities to idiopathic pulmonary fibrosis, suggesting that antifibrotic therapies may have potential positive affects. In this review, we discuss the effectiveness of antifibrotic therapy for RA-ILD.
Cite this article as: Bes C, Köybaşı G, İçaçan OC, Mutlu MY, Yıldırım F. Influence of anti-TNF-a treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study. Eur J Rheumatol. 2022;9(3):176-179.
Article Info
Published In
Journal
European Journal of Rheumatology
Volume / Issue
Volume 9 · Issue 3
Pages
176-179
History
Published Online
January 21, 2022
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright
Copyright (c) 2022 European Journal of Rheumatology
Affiliations
Cemal Bes
Department of Internal Medicine and
Rheumatology, University of Health
Sciences, Basaksehir C am and Sakura City
Hospital, _
Istanbul, Turkey
Gizem Köybaşı
Department of Chest Disease, Yedikule
Chest Diseases and Chest Surgery
Training and Research Hospital,
Istanbul, Turkey
Ozan Cemal İçaçan
Department of Rheumatology, University
of Health Sciences, Bakırko¨ y Dr. Sadi
Konuk, Training and Research Hospital,
Istanbul, Turkey
Melek Yalçın Mutlu
Department of Internal Medicine and
Rheumatology, University of Health
Sciences, Basaksehir C am and Sakura City
Hospital, _
Istanbul, Turkey
Fatih Yıldırım
Department of Internal Medicine and
Rheumatology, University of Health
Sciences, Basaksehir C am and Sakura City
Hospital, _
Istanbul, Turkey
Cite this Article
Bes, C., Köybaşı, G., İçaçan, O. C., Mutlu, M. Y., & Yıldırım, F. (2022). Antifibrotic therapies in rheumatoid arthritis associated interstitial lung disease. European Journal of Rheumatology, 9(3), 176–179. https://doi.org/10.5152/eurjrheum.2021.21102
Outlines